MNG302
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.690
- MYC_TARGETS_V2+0.632
- INTERFERON_GAMMA_RESPONSE+0.589
- UNFOLDED_PROTEIN_RESPONSE+0.520
- TNFA_SIGNALING_VIA_NFKB+0.518
- IL6_JAK_STAT3_SIGNALING+0.516
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.507
- INFLAMMATORY_RESPONSE+0.489
- ALLOGRAFT_REJECTION+0.465
- UV_RESPONSE_UP+0.429
Top 10 suppressed
- MITOTIC_SPINDLE-0.389
- G2M_CHECKPOINT-0.311
- BILE_ACID_METABOLISM-0.276
- E2F_TARGETS-0.212
- SPERMATOGENESIS-0.204
- UV_RESPONSE_DN-0.187
- PROTEIN_SECRETION-0.172
- WNT_BETA_CATENIN_SIGNALING-0.168
- FATTY_ACID_METABOLISM-0.118
- NOTCH_SIGNALING-0.118
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR820209 | GTEX | — | 0.886 |
| 2 | TCGA-BA-A6DJ-01A-11R-A30B-07 | — | — | 0.881 |
| 3 | SRR1466871 | GTEX | — | 0.880 |
| 4 | MDT-AP-2001 | Med | Medulloblastoma | 0.863 |
| 5 | TCGA-FD-A5C1-01A-11R-A28M-07 | — | — | 0.860 |
| 6 | SRR1466975 | GTEX | — | 0.858 |
| 7 | SRR1331579 | GTEX | — | 0.856 |
| 8 | SRR820133 | GTEX | — | 0.853 |
| 9 | SRR11296840 | — | — | 0.851 |
| 10 | TCGA-86-8672-01A-21R-2403-07 | — | cohortA1 | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.690 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.632 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.589 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.520 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.518 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.516 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.507 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.489 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.465 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.429 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.419 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.415 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.411 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.383 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.328 | Idelalisib | — uncovered |
| APOPTOSIS | 0.297 | Idelalisib | — uncovered |
| COAGULATION | 0.294 | Binimetinib | — uncovered |
| MYOGENESIS | 0.283 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.279 | Idelalisib | — uncovered |
| COMPLEMENT | 0.276 | Inavolisib | — uncovered |